Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET

Company Participants

Remy Bernarda - Investor Relations
George Lasezkay - Chief Executive Officer
Victor Chong - Chief Medical Officer
Charlie Deignan - Chief Financial Officer

Conference Call Participants

Jon Wolleben - JMP Securities

Operator

Greetings, and welcome to the Clearside Biomedical First Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.

I would now like to introduce your host, Remy Bernarda, Clearside Investor Relations. Please go ahead.

Remy Bernarda

Good afternoon, everyone, and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2023, that was filed March 12, 2024, and our other SEC filings available on our website.

In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. On today's call, we have George Lasezkay, our Chief Executive Officer; Dr. Victor Chong, our Chief Medical Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for questions.

I would now like to turn the call over to George.

George Lasezkay

Thank you, Remy, and good afternoon, everyone. As we near the midpoint of 2024, I'm excited with the progress we have made to date, which has positioned Clearside for an important year. Recently, we added two key positions to our team, who are having an immediate and meaningful impact on our organization. In March, we welcomed Dr. Victor Chong as our Chief Medical Officer. Victor is a well-respected board-certified retinal specialist with more than 25 years of experience advancing drug candidates through all stages of development including the development of ranibizumab and aflibercept for wet AMD.